Treatment of chronic kidney disease can slow its progression to end-stage renal disease

CKD

Treatment of chronic kidney disease (CKD) can slow its progression to end-stage renal disease (ESRD). However, the therapies remain limited. Blood pressure control using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) has the greatest weight of evidence. Glycemic control in diabetes seems likely to retard progression. Several metabolic disturbances of CKD may prove to be useful therapeutic targets but have been insufficiently tested. These include acidosis, hyperphosphatemia, and vitamin D deficiency. Drugs aimed at other potentially damaging systems and processes, including endothelin, fibrosis, oxidation, and advanced glycation end products, are at various stages of development. In addition to the paucity of proven effective therapies, the incomplete application of existing treatments, the education of patients about their disease, and the transition to ESRD care remain major practical barriers to better outcomes.

Treatment of chronic kidney disease (CKD) aims to slow progression to end-stage renal disease (ESRD) and to prepare for ESRD. Because the symptoms of chronically progressive renal failure develop slowly, therapy of CKD is usually directed at an asymptomatic condition detected only by laboratory testing. The task is also made more difficult as it usually represents a late attempt at prevention. That is, the major causes of ESRD, hypertension, and type 2 diabetes can themselves be avoided to some degree by primary preventive measures such as diet, weight control, and exercise. Furthermore, once hypertension or diabetes are manifest, their renal complications can be mitigated by secondary prevention efforts aimed at blood pressure and glycemic control. Thus, treatment of CKD often represents an example of tertiary prevention in populations who have failed the first lines of prevention but who are still relatively asymptomatic. These features make CKD therapy a formidable task in practice. However, over the past 20 years, some effective treatments of CKD have developed. These can delay and, in some cases, prevent ESRD.

The notion of CKD as a single entity with generic therapy is a simplification but a useful one. Admittedly, some forms of CKD, especially inflammatory and autoimmune ones, require special treatments. However, even these approaches are usually applied in addition to those used for the most common hypertensive and diabetic causes.

After years of research and clinical experience, it has been proved to be one of the most effective therapies. With the help of it, patient can live better and longer. If you are the patient who are in the same situation, you can chat with our online doctors or leave messages below, we will reply you as soon as possible. Or you can email us, our email: sjzkidneyhospital@hotmail.com